Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Centrally acting antihypertensive agents: a brief overview.

M A Weber, J I Drayer

    Journal of Cardiovascular Pharmacology
    |January 1, 1984
    PubMed
    Summary

    Centrally acting antihypertensive agents, like guanabenz, are effective single-drug treatments for hypertension. They offer benefits such as no sodium retention and good tolerability across diverse patient groups.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Fast, High-Fidelity Addressed Single-Qubit Gates Using Efficient Composite Pulse Sequences.

    Physical review letters·2023
    Same author

    Robust Quantum Memory in a Trapped-Ion Quantum Network Node.

    Physical review letters·2023
    Same author

    Erratum to "Second Consensus on Treatment of Patients Recently Diagnosed with Mild Hypertension and Low Cardiovascular Risk". [YMCD 45/10 (October 2020) 100653].

    Current problems in cardiology·2021
    Same author

    [Certification in cardiology : Contra: The concept should be improved].

    Herz·2018
    Same author

    Higgs physics at the CLIC electron-positron linear collider.

    The European physical journal. C, Particles and fields·2017
    Same author

    [Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].

    Der Radiologe·2017

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine
    • Internal Medicine

    Background:

    • Essential hypertension is a widespread condition requiring effective management.
    • Established antihypertensive drugs can present challenges like drug tolerance due to sodium retention.
    • Centrally acting agents represent a class of antihypertensives with distinct pharmacological properties.

    Purpose of the Study:

    • To evaluate the efficacy and safety of centrally acting antihypertensive agents, specifically guanabenz, as monotherapy for mild to moderate essential hypertension.
    • To highlight the advantages of newer agents, such as guanabenz, in overcoming limitations of older treatments.

    Main Methods:

    • Review of clinical data and studies on centrally acting antihypertensive agents.
    • Focus on guanabenz as a representative newer agent.
    • Analysis of efficacy across different demographic groups and in patients with comorbidities.

    Main Results:

    • Centrally acting agents, including guanabenz, demonstrate efficacy as single-agent therapy for essential hypertension.
    • Guanabenz does not cause sodium retention, reducing tolerance issues.
    • These agents are effective in diverse populations (age, race) and in patients with renal insufficiency.
    • Guanabenz shows efficacy in hypertensive diabetic patients without adverse effects on glucose control.
    • No significant deleterious metabolic effects observed; potential for decreased cholesterol levels.

    Conclusions:

    • Centrally acting antihypertensives are suitable for mild to moderate essential hypertension, often as first-line therapy.
    • Their broad applicability, safety profile, and lack of contraindications make them attractive treatment options.
    • Guanabenz offers a favorable profile, particularly regarding sodium balance and metabolic effects.

    Related Experiment Videos